Related references
Note: Only part of the references are listed.Sensitization of tumor cells to NK cell-mediated killing by proteasome inhibition
William H. D. Hallett et al.
JOURNAL OF IMMUNOLOGY (2008)
Nuclear factor-κB maintains TRAIL resistance in human pancreatic cancer cells
Sanaz Khanbolooki et al.
MOLECULAR CANCER THERAPEUTICS (2006)
Proteasome inhibitor drugs on the rise
Claudio A. P. Joazeiro et al.
CANCER RESEARCH (2006)
Proteasome inhibitor bortezomib modulates TLR4-induced dendritic cell activation
Alessio Nencioni et al.
BLOOD (2006)
The TRAIL apoptotic pathway mediates proteasome inhibitor induced apoptosis in primary chronic lymphocytic leukemia cells
Albert F. Kabore et al.
APOPTOSIS (2006)
IL-21 enhances tumor-specific CTL induction by anti-DR5 antibody therapy
Mark J. Smyth et al.
JOURNAL OF IMMUNOLOGY (2006)
Proteasome inhibition to maximize the apoptotic potential of cytokine therapy for murine neuroblastoma tumors
Tahira Khan et al.
JOURNAL OF IMMUNOLOGY (2006)
Aggresome disruption: A novel strategy to enhance bortezomib-induced apoptosis in pancreatic cancer cells
ST Nawrocki et al.
CANCER RESEARCH (2006)
Proteasome inhibitor-induced apoptosis in human monocyte-derived dendritic cells
A Nencioni et al.
EUROPEAN JOURNAL OF IMMUNOLOGY (2006)
TNF-related apoptosis-inducing ligand as a therapeutic agent in autoimmunity and cancer
E Cretney et al.
IMMUNOLOGY AND CELL BIOLOGY (2006)
Eradication of established tumors in mice by a combination antibody-based therapy
Tomoyasu Uno et al.
NATURE MEDICINE (2006)
Combining proteasome inhibition with TNF-related apoptosis-inducing ligand (Apo2L/TRAIL) for cancer therapy
TJ Sayers et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2006)
Bortezomib sensitizes pancreatic cancer cells to endoplasmic reticulum stress-mediated apoptosis
ST Nawrocki et al.
CANCER RESEARCH (2005)
Proteasome inhibition sensitizes hepatocellular carcinoma cells, but not human hepatocytes, to TRAIL
TM Ganten et al.
HEPATOLOGY (2005)
Proteasome inhibitors-mediated TRAIL resensitization and Bik accumulation
HB Zhu et al.
CANCER BIOLOGY & THERAPY (2005)
Cooperative cytotoxicity of proteasome inhibitors and tumor necrosis factor-related apoptosis-inducing ligand in chemoresistant Bcl-2-overexpressing cells
A Nencioni et al.
CLINICAL CANCER RESEARCH (2005)
Bortezomib abolishes tumor necrosis factor-related apoptosis-inducing ligand resistance via a p21-dependent mechanism in human bladder and prostate cancer cells
LM Lashinger et al.
CANCER RESEARCH (2005)
The anti-tumor effect of Apo2L/TRAIL on patient pancreatic adenocarcinomas grown as xenografts in SCID mice
BL Hylander et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2005)
Mitochondrial-mediated disregulation of Ca2+ is a critical determinant of Velcade (PS-341/Bortezomib) cytotoxicity in myeloma cell lines
TH Landowski et al.
CANCER RESEARCH (2005)
Enhanced apoptosis and tumor regression induced by a direct agonist antibody to tumor necrosis factor related apoptosis-inducing ligand receptor 2
K Motoki et al.
CLINICAL CANCER RESEARCH (2005)
Evidence for a protective role of Mcl-1 in proteasome inhibitor-induced apoptosis
A Nencioni et al.
BLOOD (2005)
Overview of cell death signaling pathways
ZY Jin et al.
CANCER BIOLOGY & THERAPY (2005)
Proteasome inhibitor MG132 upregulates death receptor 5 and cooperates with Apo2L/TRAIL to induce apoptosis in Bax-proficient and -deficient cells
Q He et al.
ONCOGENE (2004)
Induction of tumor-specific T cell immunity by anti-DR5 antibody therapy
K Takeda et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2004)
Inhibition of NF-κB in cancer cells converts inflammation-induced tumor growth mediated by TNFα to TRAIL-mediated tumor regression
JL Luo et al.
CANCER CELL (2004)
Interleukin-7 inactivates the pro-apoptotic protein bad promoting T cell survival
WQ Li et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2004)
Inhibition of acute graft-versus-host disease with retention of graft-versus-tumor effects by the proteasome inhibitor bortezomib
K Sun et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2004)
The proteasome inhibitor PS-341 overcomes TRAIL resistance in Bax and caspase 9-negative or Bcl-xL overexpressing cells
TR Johnson et al.
ONCOGENE (2003)
The proteasorne inhibitor PS-341 sensitizes neoplastic cells to TRAIL-mediated apoptosis by reducing levels of c-FLIP
TJ Sayers et al.
BLOOD (2003)
Apo2L/TRAIL: apoptosis signaling, biology, and potential for cancer therapy
A Almasan et al.
CYTOKINE & GROWTH FACTOR REVIEWS (2003)
A unified model for apical caspase activation
KM Boatright et al.
MOLECULAR CELL (2003)
Proteasome inhibition results in TRAIL sensitization of primary keratinocytes by removing the resistance-mediating block of effector caspase maturation
M Leverkus et al.
MOLECULAR AND CELLULAR BIOLOGY (2003)
Nature's TRAIL - On a path to cancer immunotherapy
MJ Smyth et al.
IMMUNITY (2003)
The CD95(APO-1/Fas) DISC and beyond
ME Peter et al.
CELL DEATH AND DIFFERENTIATION (2003)
Tumor-specific CTL kill murine renal cancer cells using both perforin and Fas ligand-mediated lysis in vitro, but cause tumor regression in vivo in the absence of perforin
N Seki et al.
JOURNAL OF IMMUNOLOGY (2002)
Increased susceptibility to tumor initiation and metastasis in TNF-related apoptosis-inducing ligand-deficient mice
E Cretney et al.
JOURNAL OF IMMUNOLOGY (2002)
Critical role for tumor necrosis factor-related apoptosis-inducing ligand in immune surveillance against tumor development
K Takeda et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2002)
TRAIL/Apo2L ligand selectively induces apoptosis and overcomes drug resistance in multiple myeloma: therapeutic applications
CS Mitsiades et al.
BLOOD (2001)
Involvement of tumor necrosis factor-related apoptosis-inducing ligand in surveillance of tumor metastasis by liver natural killer cells
K Takeda et al.
NATURE MEDICINE (2001)
Share Paper
